Explore

Heavy Caffeine Consumption Linked to Deeper NREM Sleep Despite Shorter Total Sleep Time, Study Finds

Heavy Caffeine Consumption Linked to Deeper NREM Sleep Despite Shorter Total Sleep Time, Study Finds

New research published in the Journal of Psychopharmacology indicates that individuals who consume four or more caffeinated drinks daily experience shorter overall sleep durations but exhibit deeper non-rapid-eye-movement (NREM) sleep. The study analyzed data from over 485,000 participants in the UK Biobank and 1,700 individuals from the HypnoLaus cohort. While sleep quality ratings and chronotype (morning or evening person) were not dependent on caffeine intake, a significant association was found between high caffeine consumption and reduced total sleep time. However, a surprising finding was the increased depth of NREM sleep in heavy caffeine users, suggesting a potential compensatory mechanism. Sleep medicine physicians, including Dr. Beth Malow of Vanderbilt Health and Dr. W. Christopher Winter of Charlottesville Neurology and Sleep Medicine, caution that these findings do not imply caffeine is beneficial for sleep, but rather a response to overall decreased sleep from caffeine use.

Consistent Sleep Routines and REM Sleep Linked to Reduced Disease Risk

Consistent Sleep Routines and REM Sleep Linked to Reduced Disease Risk

A new study published in PLOS Medicine, analyzing data from nearly 100,000 adults in the UK Biobank, indicates that increased Rapid Eye Movement (REM) sleep is associated with a lower risk of over 80 health conditions, including heart failure, hypertension, and dementias. Additionally, more deep sleep was linked to a reduced risk of seven diseases. Conversely, greater time spent in light sleep, a marker of poorer sleep quality, was associated with a higher risk of conditions like major depressive disorder. The study also found that irregular sleep patterns and higher wakefulness after sleep onset (WASO) scores were linked to increased risks of various health issues, such as anxiety and psychoactive substance dependence. Experts emphasize the importance of consistent sleep schedules, recommending individuals wake up at roughly the same time daily, even on weekends, to help regulate the brain's sleep-wake patterns. Optimal sleep duration is suggested to be between 6-8 hours.

Building a Consistent Sleep Routine Prioritizes Wake Time Over Trackers

Building a Consistent Sleep Routine Prioritizes Wake Time Over Trackers

Building a Consistent Sleep Routine Prioritizes Wake Time Over Trackers

Retinal Scans May Predict Atrial Fibrillation Risk Years in Advance, Study Suggests

Retinal Scans May Predict Atrial Fibrillation Risk Years in Advance, Study Suggests

A new study involving over 90,000 individuals suggests that thinning in a specific layer of nerve tissue in the retina could indicate a significantly higher risk of developing atrial fibrillation (AFib) years before a formal diagnosis. Researchers found that for every step of thinning measured in the ganglion cell-inner plexiform layer of the retina, individuals faced a 27% higher risk of developing AFib later. This thinning was observed consistently across two large study groups, one from a London eye hospital and another from the UK Biobank, which tracked participants for approximately a decade. The study highlights that these retinal changes were detectable before AFib was clinically diagnosed, offering a potential early warning sign for a condition often difficult to catch due to its intermittent and sometimes asymptomatic nature. The retina's shared blood vessels and nerve tissue with the brain and heart make it a potential 'window' into broader cardiovascular health.

US regulators examine testosterone therapy for women as experts debate evidence, safety

US regulators examine testosterone therapy for women as experts debate evidence, safety

By Siddhi Mahatole and Padmanabhan Ananthan Sept 17 (Reuters) - US health regulators weighing testosterone use in menopausal women at a public meeting on Thursday were told by some experts that a female-specific product was needed while others pointed to gaps in evidence on the hormone's broader

Medical Practices Advised to Prioritize Honest Communication in Hormone Replacement Therapy Marketing

Medical Practices Advised to Prioritize Honest Communication in Hormone Replacement Therapy Marketing

Medical practices offering hormone replacement therapy (HRT) are being urged to adopt transparent and honest marketing strategies, moving away from potentially misleading terms like 'natural' or 'bioidentical' when promoting compounded hormone preparations. According to Target Patients MD, these terms, while appealing to patients, are often not supported by federal regulators and major endocrine and menopause societies. The firm highlights that patients seeking HRT are often well-read but also fearful, having encountered conflicting information. Therefore, marketing should focus on the comprehensive care provided, including evaluation, monitoring, dose adjustments, and long-term supervision, rather than making unsubstantiated claims about product superiority. The emphasis should be on building trust through clear explanations of risks and benefits, tailored to individual patient needs and re-evaluated over time. This approach is crucial for retaining patients in a long-term care model, as HRT is not a one-...

Aloe Vera Juice: Benefits and Risks Clarified by Health Experts

Aloe Vera Juice: Benefits and Risks Clarified by Health Experts

Aloe Vera Juice: Benefits and Risks Clarified by Health Experts

Representative Glenn Grothman Addresses Oral Chemotherapy Affordability in House Oversight Hearing

Representative Glenn Grothman Addresses Oral Chemotherapy Affordability in House Oversight Hearing

Representative Glenn Grothman, serving as Chairman of the House Oversight Subcommittee on Health Care and Financial Services, led a hearing on September 15, 2026, titled 'Unequal Treatment: Addressing the Drivers of Unaffordability for Oral Chemotherapy.' The hearing focused on the disparity in out-of-pocket costs for oral versus intravenous chemotherapy treatments. Chairman Grothman's opening remarks highlighted the significant role of insurers and pharmacy benefit managers (PBMs) in the oral-drug supply chain. He argued that current benefit designs, pharmacy networks, and utilization-management rules often lead to high out-of-pocket costs and treatment delays for patients. The witness panel, comprising representatives from oncology practices, academic cancer care, and patient advocacy, discussed the financial and administrative hurdles patients face in accessing oral cancer medicines. The discussion explored how pharmacy-benefit coverage can differ from medical-benefit coverage for infused drugs, and how...

Trilliome Introduces TRI-01, a Precision Activator for Keystone Gut Bacteria

Trilliome Introduces TRI-01, a Precision Activator for Keystone Gut Bacteria

Trilliome Introduces TRI-01, a Precision Activator for Keystone Gut Bacteria

FDA Approves New Warnings for Kybella Injections Due to Adverse Reactions from Unapproved Use

FDA Approves New Warnings for Kybella Injections Due to Adverse Reactions from Unapproved Use

The U.S. Food and Drug Administration (FDA) has approved significant updates to the labeling for Kybella (deoxycholic acid) injection. These updates include new warnings regarding adverse reactions that can occur when the drug is used outside its approved indication, which is for submental fat (under the chin). The FDA now explicitly recommends against this unapproved use. This decision follows a comprehensive review of reports from the FDA Adverse Event Reporting System (FAERS) and medical literature, which revealed that administering Kybella outside the submental fat region can lead to serious neuromuscular and other adverse events. Additionally, the FDA has added language to the Warnings and Precautions section concerning the serious risks of injection site nodules (3 cm or smaller) and masses (larger than 3 cm). These nodules and masses may not resolve over time and could require medical intervention, occurring even when Kybella is used as indicated in the submental area, as well as in unapproved areas...

Cell and Gene Therapy Industry Faces Scale-Up Challenges, Lifecycle Approach Proposed

Cell and Gene Therapy Industry Faces Scale-Up Challenges, Lifecycle Approach Proposed

Cell and Gene Therapy Industry Faces Scale-Up Challenges, Lifecycle Approach Proposed

Ayurveda Day 2026 to Emphasize Evidence-Based Research and Global Integration

Ayurveda Day 2026 to Emphasize Evidence-Based Research and Global Integration

Ayurveda, a traditional Indian healing system, is advancing with a focus on evidence-based research and innovation. The 11th Ayurveda Day, scheduled for September 23, 2026, will be celebrated under the theme "Ayurveda for a Healthy Future." This event aims to connect Ayurveda with modern research, quality standards, and international healthcare frameworks. For the first time since its inception in 2016, Ayurveda Day will be observed on a fixed date, September 23rd, annually, as notified by the Government of India in March 2025. This decision marks a significant shift from its previous observance on Dhanvantari Jayanti (Dhanteras), providing Ayurveda with a universal calendar identity and fostering greater global participation and credibility. The initiative seeks to raise awareness that Ayurveda is an evidence-based scientific medical system and to promote its integration into global healthcare.